Dr. Shafeeq Ladha from Barrow Neurological Institute will review the clinical trial of Actemra in ALS patients and provide a trial update. He will discuss the rationale for using the drug, the role of inflammation in ALS progression and the addition of the [11C]PBR28-PET scan to the study protocol.
